← Back to Search

Benzodiazepine

A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants

Phase 1
Waitlist Available
Research Sponsored by UCB Biopharma SRL
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline (day 1) of treatment period 1 to the end of safety follow-up (up to 25 days)
Awards & highlights
No Placebo-Only Group

Summary

This trial compares how well the body absorbs alprazolam when taken by mouth versus when inhaled. It involves individuals who need to take alprazolam and measures the amount of medication in the bloodstream. Alprazolam is commonly used to treat anxiety.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline (day 1) of treatment period 1 to the end of safety follow-up (up to 25 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline (day 1) of treatment period 1 to the end of safety follow-up (up to 25 days) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Area under the plasma concentration-time curve from time 0 to infinity (AUC) of alprazolam
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC(0-t)) of alprazolam
Maximum plasma concentration (Cmax) of alprazolam
Secondary study objectives
Percentage of study participants with serious treatment-emergent adverse events (serious TEAEs)
Percentage of study participants with treatment-emergent adverse events (TEAEs)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Treatment Sequence BAExperimental Treatment2 Interventions
Study participants randomized into this arm will receive single dose of oral alprazolam followed by single dose of Staccato alprazolam at pre-specified time points in the sequence BA.
Group II: Treatment Sequence ABExperimental Treatment2 Interventions
Study participants randomized into this arm will receive single dose of Staccato alprazolam followed by single dose of oral alprazolam at pre-specified time points in the sequence AB.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Staccato alprazolam
2022
Completed Phase 1
~30
Oral alprazolam
2011
Completed Phase 3
~250

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

UCB Biopharma SRLLead Sponsor
115 Previous Clinical Trials
22,885 Total Patients Enrolled
UCB CaresStudy Director001 844 599 2273 (UCB)
219 Previous Clinical Trials
46,259 Total Patients Enrolled
~7 spots leftby Dec 2025